Welcome to our dedicated page for Nano-X Imaging Ltd. SEC filings (Ticker: NNOX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Nanox Imaging Ltd’s journey from novel nanotechnology to FDA-cleared X-ray systems means diving into dense disclosures that mingle medical-device regulations with subscription-style revenue models. Locating R&D spending, approval milestones, or executive stock sales inside a 300-page document can feel overwhelming. That’s why investors searching for "Nanox insider trading Form 4 transactions" or "how to read a Nanox annual report 10-K" start here.
Stock Titan’s AI breaks down every Nanox filing in real time. Need the latest "Nanox quarterly earnings report 10-Q filing"? We post it within minutes of hitting EDGAR and pair it with plain-English summaries that spotlight cost-per-scan economics, cloud-service adoption, and regulatory risk updates. Curious about material events? Our platform tags each 8-K so you can skim "Nanox 8-K material events explained" instead of scrolling line by line. Insider activity is equally transparent: receive "Nanox Form 4 insider transactions real-time" alerts to monitor executive buys and sells the moment they’re reported.
Here’s what you’ll find on this page:
- AI-powered digests that make "understanding Nanox SEC documents with AI" effortless
- Side-by-side views of the full text and concise takeaways for every 10-K, 10-Q, and 8-K
- Filters for "Nanox proxy statement executive compensation" details and governance votes
- Instant notifications on "Nanox executive stock transactions Form 4" to track insider sentiment
- Historical archives for comparative "Nanox earnings report filing analysis" across quarters
Whether you’re evaluating commercialization progress or monitoring dilution risk, our comprehensive, continually updated feed ensures Nanox SEC filings are explained simply, accurately, and on your schedule.
Nano-X Imaging Ltd reports a registered direct offering to a single institutional investor of 3,826,530 ordinary shares at $3.92 per share. The transaction is expected to generate approximately $15.0 million in gross proceeds after deducting placement agent fees and other offering expenses payable by the company, which will be used for working capital and general corporate purposes.
Titan Partners Group LLC, a division of American Capital Partners, LLC, acted as sole placement agent under a placement agency agreement. For 10 days after the placement agency agreement date, Nanox agreed not to issue or agree to issue additional ordinary shares or equivalents, or file new registration statements other than limited exceptions. Company officers and directors entered 30‑day lock-up agreements after the closing, restricting sales or other disposals of ordinary shares and related securities without the placement agent’s consent.
Nano-X Imaging Ltd is issuing 3,826,530 ordinary shares in a registered direct offering to a single institutional investor at $3.92 per share, raising gross proceeds of about $15.0 million. After placement agent fees and expenses, the company expects net proceeds of approximately $14.2 million, which it plans to use for general working capital and corporate purposes.
The offering implies an immediate dilution of about $2.35 per share to the new investor, based on an as adjusted net tangible book value of $1.57 per share as of September 30, 2025. As context, there were 65,382,892 ordinary shares outstanding as of September 30, 2025, so this deal modestly increases the share count. Nanox also highlights recent milestones, including expanded FDA clearances, a CE mark in Europe for its Nanox.ARC system, and a proposed acquisition of VHC IT for up to $800,000 to support U.S. deployment of its AI imaging solutions.
Nanox Imaging Ltd entered into a securities purchase agreement with a single institutional investor for a registered direct offering of 3,826,530 ordinary shares at $3.92 per share. The agreement includes customary representations, warranties, and indemnification provisions for both the company and the purchaser. Closing of the offering is expected on November 25, 2025, subject to customary closing conditions. The company also furnished a related press release as an exhibit and reminded readers that any forward-looking statements are subject to significant business, regulatory, geopolitical, and macroeconomic risks.
NANO-X IMAGING LTD filed a Form 6-K reporting that it issued a press release on November 20, 2025, furnishing its latest financial results. The company explains that the press release includes both U.S. GAAP financial information and additional non-GAAP financial measures that exclude certain expenses required under GAAP, and directs readers to the press release for details on those adjustments.
The GAAP financial statement tables in the press release are incorporated by reference into Nano-X Imaging’s existing registration statements on Form F-3 (File No. 333-271688) and Form S-8 (File No. 333-248322), linking the updated financial information to previously filed offerings and equity compensation plans.
NANO-X IMAGING LTD reported that it will hold its Annual General Meeting of Shareholders on December 22, 2025 at 3:00 p.m. Israel time (8:00 a.m. EST) at its offices in Ofer Tech Park, Petach Tikva, Israel. Shareholders are being provided with a Notice and Proxy Statement and a Proxy Card, which are attached as exhibits to this report. The company also states that the information in this report is incorporated by reference into its existing registration statements on Form F-3 (File No. 333-271688) and Form S-8 (File No. 333-248322).
Daniel Ran, listed as the Chief Financial Officer of Nano-X Imaging Ltd. (NNOX), reported a direct purchase of ordinary shares on 09/05/2025. The Form 4 shows he acquired 1,000 ordinary shares at a price of $3.65 per share and, following the transaction, beneficially owned 6,950 ordinary shares in total. The filing indicates this is an individual filing by one reporting person and includes no derivative transactions.
Daniel Ran filed an Initial Statement of Beneficial Ownership (Form 3) for Nano-X Imaging Ltd. (NNOX) dated 09/05/2025. The filing shows Mr. Ran is an officer (CFO) and a director and beneficially owns 5,950 ordinary shares directly. He also holds two option grants exercisable for ordinary shares: 40,000 options exercisable from 09/30/2022 and expiring 09/30/2031 with an exercise price of $23.86, and 55,000 options exercisable from 05/23/2024 and expiring 05/23/2033 with an exercise price of $11.52. The filing lists a Forest Hills, NY address for the reporting person and is signed by Daniel Ran on 09/05/2025.
FAQ
What is the current stock price of Nano-X Imaging Ltd. (NNOX)?
What is the market cap of Nano-X Imaging Ltd. (NNOX)?
